Randomized phase II trial in prostate cancer with hormone-sensitive OligometaSTatic relapse: Combining stereotactic ablative radiotherapy and durvalumab (POSTCARD GETUG P13): Study protocol

Moreno, 2014, Oligometastases in prostate cancer: restaging stage IV cancers and new radiotherapy options, Radiat Oncol, 9, 258, 10.1186/s13014-014-0258-7 Schweizer, 2013, Metastasis-free survival is associated with overall survival in men with PSA-recurrent prostate cancer treated with deferred androgen deprivation therapy, Ann Oncol, 24, 2881, 10.1093/annonc/mdt335 Ost, 2014, Prognostic factors influencing prostate cancer-specific survival in non-castrate patients with metastatic prostate cancer: Oligometastatic Prostate Cancer, Prostate, 74, 297, 10.1002/pros.22750 Phillips, 2020, Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial, JAMA Oncol, 6, 650, 10.1001/jamaoncol.2020.0147 Ost, 2018, Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial, J Clin Oncol, 36, 446, 10.1200/JCO.2017.75.4853 Siva, 2018, Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial, Eur Urol, 74, 455, 10.1016/j.eururo.2018.06.004 Bowden, 2020, Fractionated stereotactic body radiotherapy for up to five prostate cancer oligometastases: Interim outcomes of a prospective clinical trial, Int J Cancer, 146, 161, 10.1002/ijc.32509 Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence (STOMP): Five-year results of a randomized phase II trial. | Journal of Clinical Oncology [Internet]. [cited 2021 Dec 8]. Available from: https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.6_suppl.10. Bhattasali, 2013, Rationale for Stereotactic Body Radiation Therapy in Treating Patients with Oligometastatic Hormone-Naïve Prostate Cancer, Front Oncol [Internet], 10.3389/fonc.2013.00293 EAU Guidelines. Edn. presented at the EAU Annual Congress Amsterdam 2022. ISBN 978-94-92671-16-5. Dai, 2014, The PD-1/PD-Ls pathway and autoimmune diseases, Cell Immunol, 290, 72, 10.1016/j.cellimm.2014.05.006 Bellmunt, 2017, Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma, N Engl J Med, 376, 1015, 10.1056/NEJMoa1613683 Motzer, 2019, Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial, Lancet Oncol, 20, 1370, 10.1016/S1470-2045(19)30413-9 Elia, 2018, Immune Checkpoint-Mediated Interactions Between Cancer and Immune Cells in Prostate Adenocarcinoma and Melanoma, Front Immunol, 31, 1786, 10.3389/fimmu.2018.01786 Antonarakis, 2020, Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study, J Clin Oncol, 38, 395, 10.1200/JCO.19.01638 Sharma, 2020, Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial, Cancer Cell, 38, 489, 10.1016/j.ccell.2020.08.007 Philippou, 2020, Impacts of combining anti-PD-L1 immunotherapy and radiotherapy on the tumour immune microenvironment in a murine prostate cancer model, Br J Cancer, 123, 1089, 10.1038/s41416-020-0956-x Ollivier, 2021, Interaction Between Modern Radiotherapy and Immunotherapy for Metastatic Prostate Cancer, Front Oncol, 14 Seymour, 2017, iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics, Lancet Oncol, 18, e143, 10.1016/S1470-2045(17)30074-8 Cox, 2012, International Spine Radiosurgery Consortium Consensus Guidelines for Target Volume Definition in Spinal Stereotactic Radiosurgery, Int J Radiat Oncol, 83, e597, 10.1016/j.ijrobp.2012.03.009 Hanna, 2018, UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy, Clin Oncol, 30, 5, 10.1016/j.clon.2017.09.007 A’Hern, 2001, Sample size tables for exact single-stage phase II designs, Stat Med, 20, 859, 10.1002/sim.721